DBV Technologies S.A.(DBVT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,955 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
DBVT Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for DBV Technologies S.A. (DBVT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores DBVT at 4.6/100 on a 32-signal composite quality model, placing it at rank #2,955 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), DBV Technologies S.A. reports quarterly revenue of $700.0K, net income of $-50.4M, free cash flow of $-53.0M. Top institutional holders of DBVT by reported 13-F value include MPM BioImpact, Siren, L.L.C., Vivo Capital, based on the most recent SEC filings. DBVT trades on the Nasdaq exchange and files with the SEC under CIK 1613780. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DBVT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for DBV Technologies S.A. directly from SEC EDGAR. DBV Technologies S.A.'s 13F Pro composite quality score has ranged between 5 and 22 since 2024, currently 4.6 — a stable long-term trajectory across 30 quarterly and live scoring snapshots.
Revenue
Q2 2026
$700.0K
Net Income
Q2 2026
$-50.4M
Free Cash Flow
Q2 2026
$-53.0M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+35.8% YoYNet Income
-229.0% YoYOperating Income
-26.1% YoYEPS (Diluted)
+10.3% YoYTotal Assets
+255.9% YoYTotal Debt
Op. Cash Flow
-16.0% YoYFree Cash Flow
-14.0% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $5.6M +35.8% | $4.2M -73.6% | $15.7M +224.7% | $4.8M -15.1% | $5.7M -49.4% | $11.3M |
| Net Income | $-146.9M -229.0% | $113.9M +56.7% | $72.7M -24.5% | $96.3M +198.4% | $-97.8M +38.7% | $-159.6M |
| Operating Income | $-147.1M -26.1% | $-116.6M -52.5% | $-76.4M +20.9% | $-96.6M +2.0% | $-98.6M +37.9% | $-158.8M |
| EPS (Diluted) | $-1.05 +10.3% | $-1.17 -53.9% | $-0.76 +38.7% | $-1.24 +30.3% | $-1.78 | — |
| Total Assets | $233.7M +255.9% | $65.7M -64.1% | $183.0M -25.8% | $246.5M +68.0% | $146.7M -46.1% | $272.2M |
| Total Debt | — | — | — | — | $510.0K -59.7% | $1.3M |
| Operating Cash Flow | $-121.2M -16.0% | $-104.5M -31.2% | $-79.7M -43.1% | $-55.7M +48.6% | $-108.2M +34.6% | $-165.6M |
| Free Cash Flow | $-121.7M -14.0% | $-106.8M -33.0% | $-80.3M -42.4% | $-56.4M +48.3% | $-109.2M +35.2% | $-168.4M |
Get alerted when DBVT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for DBV Technologies S.A. including:
Top Institutional Holders of DBVT
MPM BioImpact LLC
$60.1M3,666,284 shSiren, L.L.C.
$30.5M1,857,362 shVivo Capital, LLC
$30.3M1,844,758 shPERCEPTIVE ADVISORS LLC
$27.1M1,653,350 shBAKER BROS. ADVISORS LP
$24.0M1,461,425 shArtisan Partners Limited Partnership
$22.5M1,372,851 shUBS Group AG
$21.5M1,313,439 shMORGAN STANLEY
$15.7M954,908 shLogos Global Management LP
$15.0M915,000 shPatient Square Capital LP
$14.9M909,474 sh
| Fund | Value | Shares |
|---|---|---|
| MPM BioImpact LLC | $60.1M | 3,666,284 |
| Siren, L.L.C. | $30.5M | 1,857,362 |
| Vivo Capital, LLC | $30.3M | 1,844,758 |
| PERCEPTIVE ADVISORS LLC | $27.1M | 1,653,350 |
| BAKER BROS. ADVISORS LP | $24.0M | 1,461,425 |
| Artisan Partners Limited Partnership | $22.5M | 1,372,851 |
| UBS Group AG | $21.5M | 1,313,439 |
| MORGAN STANLEY | $15.7M | 954,908 |
| Logos Global Management LP | $15.0M | 915,000 |
| Patient Square Capital LP | $14.9M | 909,474 |
Companies Similar to DBVT
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Tango Therapeutics, Inc.
Silence Therapeutics plc
Kymera Therapeutics, Inc.
Invivyd, Inc.
Viridian Therapeutics, Inc.\DE
Dianthus Therapeutics, Inc. /DE/
RHYTHM PHARMACEUTICALS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put DBVT on your watchlist
Track score changes the day DBV Technologies S.A. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DBVT a good stock to buy?
13F Pro's AI-powered analysis of DBV Technologies S.A. (DBVT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DBVT are available on the DBVT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. DBVT is classified as a mid company.
Which hedge funds own DBVT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DBVT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of DBV Technologies S.A.'s investment landscape.